Recurrent, rapidly growing nasal polyps are hallmarks of aspirin-exacerbated respiratory disease (AERD), although the mechanisms of polyp growth have not been identified. Fibroblasts are intimately involved in tissue remodeling, and the growth of fibroblasts is suppressed by prostaglandin E 2 (PGE 2 ), which elicits antiproliferative effects mediated through the E prostanoid (EP) 2 receptor. We now report that cultured fibroblasts from the nasal polyps of subjects with AERD resist this antiproliferative effect. Fibroblasts from polyps of subjects with AERD resisted the antiproliferative actions of PGE 2 and a selective EP 2 agonist (P , 0.0001 at 1 mM) compared with nasal fibroblasts from aspirin-tolerant control subjects undergoing polypectomy or from healthy control subjects undergoing concha bullosa resections. Cell surface expression of the EP 2 receptor protein was lower in fibroblasts from subjects with AERD than in fibroblasts from healthy control subjects and aspirin-tolerant subjects (P , 0.01 for both). Treatment of the fibroblasts with trichostatin A, a histone deacetylase inhibitor, significantly increased EP 2 receptor mRNA in fibroblasts from AERD and aspirin-tolerant subjects but had no effect on cyclooxygenase-2, EP 4 , and microsomal PGE synthase 1 (mPGES-1) mRNA levels. Histone acetylation (H3K27ac) at the EP 2 promoter correlated strongly with baseline EP 2 mRNA (r = 0.80; P , 0.01). These studies suggest that the EP 2 promotor is under epigenetic control, and one explanation for PGE 2 resistance in AERD is an epigenetically mediated reduction of EP 2 receptor expression, which could contribute to the refractory nasal polyposis typically observed in this syndrome.